The IPV Vaccines Market Is Estimated To Witness High Growth Owing To Increasing Government Initiatives And Growing Disease Burden
![]() |
IPV vaccines |
The IPV vaccines market is estimated to be valued at US$ 174 Mn in 2023 and is expected to exhibit a CAGR of 8.5% over the forecast period
of 2021 to 2028, as highlighted in a new report published by Coherent Market
Insights.
Market Overview:
Inactivated poliovirus vaccines (IPV) are vaccines made from inactivated
(killed) poliovirus. The inactivated viruses cannot cause polio. Three forms of
polio virus (types 1, 2, and 3) exist and must all be present in order for the
polio vaccine to provide full protection from disease. IPV vaccines offer
protection against paralytic polio and are given by injection, usually in the
leg or arm, depending on the patient's age. IPV vaccines play a crucial role in
eradicating polio across the globe through mass immunization programs.
Market Dynamics:
The increasing government initiatives for polio eradication programs are
expected to augment the growth of the IPV vaccines market over the forecast
period. For instance, the Global Polio Eradication Initiative (GPEI), which is
spearheaded by national governments, World Health Organization (WHO), Rotary
International, the US Centers for Disease Control and Prevention (CDC), UNICEF,
and Bill & Melinda Gates Foundation are focusing on increasing the usage of
IPV vaccines. Furthermore, the growing disease burden of poliomyelitis across
developing and underdeveloped nations is also fueling the demand for IPV
vaccines.
SWOT Analysis
Strength: Explain in three sentence explanation
- Strong R&D capabilities and focus on developing novel IPV vaccines.
Several clinical trials are ongoing.
- Growing government support for vaccination programs globally. Strong
government policies for immunization.
- Established distribution channels of major players across countries. Strong
supply chain network.
Weakness: Explain two weakness in three sentence long explanation
- High costs associated with production of IPV vaccines. Requires complex
manufacturing processes increasing production costs.
- Dependence on governments for bulk purchases. Uncertainty associated with
changes in government vaccination policies and funding.
Opportunity: Explain two opportunity in three sentence long explanation
- Untapped growth opportunities in developing regions of Asia Pacific and
Africa. Scope for expansion in countries with large population base.
- Collaborations with UNICEF and WHO for immunization programs in low and
middle-income countries provide new business avenues.
Threats: Explain two threats two sentence explanation
- Threat from emerging novel alternative vaccines and therapeutic areas. Shift
towards newer vaccine technologies.
- Intense competition amongst existing players. Pricing pressure due to
competition.
Key Takeaways
The Global
IPV Vaccines Market is expected to witness high growth, exhibiting CAGR of 8.5% over the forecast period,
due to increasing government focus on immunization programs across countries.
Several countries have IPV incorporated in their national immunization
schedules boosting market revenues.
Regional analysis: Asia Pacific is expected to witness fastest growth in the
global IPV vaccines market owing to rising healthcare expenditures, growing
population and ongoing government initiatives to strengthen immunization
programs in populous countries like India and China. North America dominates
the global IPV vaccines market currently with the US being the major revenue
generating country.
Key players: Key players operating in the IPV vaccines market are
GlaxoSmithKline Plc, Sanofi S.A., Serum Institute of India Pvt. Ltd., PT Bio
Farma, and AJ Vaccines. Major players are focusing on expanding their
geographical presence through collaborations with local players especially in
developing markets of Asia and Africa.
Comments
Post a Comment